Dennis Keefe
Chief Scientific Officer Complement Therapeutics
Dennis has over 20 years of experience as a drug developer, holding positions of increasing responsibility at Millenium Pharmaceuticals, Shire Human Genetic Therapies, Stealth Biotherapeutics, and most recently Prothelia, where as CSO he led all preclinical and nonclinical development efforts. Dennis brings a wealth of experience across multiple therapeutic areas, encompassing Autoimmune Disease, Neuromuscular and Neurodegenerative Disease, Neonatology and Ophthalmology, and has significant technical expertise in diverse therapeutic modalities.
Seminars
Wednesday 9th December 2026
Panel Discussion: Strategizing the Future of Complement Therapeutics Beyond Nephrology by Overcoming Biological, Translational & Development Bottlenecks to Treat a Plethora of Diseases
5:00 pm
- Discussing how emerging biology and novel mechanisms are expanding the therapeutic potential of complement beyond nephrology
- Exploring solutions to delivery, target engagement and sample collection challenges in difficult-to-access tissues
- Identifying the key factors for success in new indications, including target selection, patient stratification and translational validation
Thursday 10th December 2026
Advancing Gene Therapy Approaches for Complement-Mediated Diseases to Achieve Long-Term Therapeutic Benefit with Reduced Dosing Requirements
9:30 am
- Evaluating the potential of gene therapies to provide sustained complement modulation
- Overcoming delivery, durability and safety challenges to maximize therapeutic benefit across systemic and tissue-specific diseases
- Sharing lessons learned from development pipelines to accelerate the translation of gene therapy approaches into approved treatments
